April 5, 2013
Agios Research in Cancer Metabolism Highlighted at AACR Annual Meeting 2013
April 4, 2013
Foundation Medicine and Agios Announce Diagnostic Discovery Collaboration for IDH1 and IDH2 Cancer Metabolism Programs
April 4, 2013
Agios Publishes Two Articles in Science Demonstrating the Effects of Mutant IDH1 and IDH2 Inhibitors in Primary Tumor Models
February 26, 2013
Agios Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
February 22, 2013
Agios to Present IDH Program Insights at Tumor Metabolism Keystone Symposia
February 13, 2013
New Publication in Science Shows That Agios IDH1 Inhibitor Can Reverse Cancer-Causing Effects of Oncometabolite 2HG in Leukemia Model
February 6, 2013
Agios Pharmaceuticals to Present at the Leerink Swann 2013 Global Healthcare Conference
January 28, 2013
Target Cancer Metabolism Conference to Feature Three Presentations by Agios Scientists
January 3, 2013
Agios Pharmaceuticals, Inc. to Present at 31st Annual J.P. Morgan Healthcare Conference
October 11, 2012
Agios Publication Identifies First PotentInhibitors of Mutant IDH1 that Lower Tumor Oncometabolite
September 20, 2012
New Publications from Agios Scientists and Collaborators Reveal Unexpected Regulation of Metabolic Pathways in Cancer
September 13, 2012
Agios Pharmaceuticals to Present at the UBS Global Life Sciences Conference
August 31, 2012
Agios Pharmaceuticals, Inc. and The University of Pennsylvania Announce New Collaboration
July 5, 2012
Nature Publication from Agios Scientists and Co-founder Reinforces Link Between Key Metabolic Enzyme IDH and Cancer
June 22, 2012
BIO Welcomes David Schenkein, M.D., to the Emerging Companies Section Governing Board
May 29, 2012
Agios Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
May 3, 2012
Agios Strengthens Team with Key Appointments and Promotion
April 3, 2012
Agios Research in Cancer Metabolism Highlighted at AACR Annual Meeting 2012
February 29, 2012
Agios Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
February 9, 2012
Agios Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
January 3, 2012
Agios Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
November 17, 2011
Agios Secures $78 Million in Oversubscribed Series C Financing
November 1, 2011
Celebrating 16 Years of Cancer Support at Gildaâ??s Club NYC
October 5, 2011
Celgene and Agios Extend Cancer Metabolism Collaboration
September 20, 2011
Marc Tessier-Lavigne, Ph.D., President of The Rockefeller University, Joins Agios Board of Directors
August 2, 2011
Agios Founder and Advisor Publish In Nature Genetics On Further Links Between Serine Metabolic Pathway and Cancer
July 14, 2011
Agios and Whitehead Institute Collaborate on Nature Publication Revealing Altered Metabolic Pathway in Breast Cancer
March 1, 2011
Agios Pharmaceuticals to Present at 31st Annual Cowen Healthcare Conference
January 6, 2011
Agios Pharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
December 14, 2010
Agios Announces Cancer Cell Publication of Research Illuminating Link between Cancer Metabolism and Epigenetics
November 4, 2010
Agios Awarded Two Federal Grants to Advance Cancer Metabolism Focused Therapeutics
September 20, 2010
Agios Appoints Scott Biller, Ph.D., Industry Leader and Drug Developer, as Chief Scientific Officer
July 29, 2010
Agios Creates Expanded Scientific Advisory Role for Lewis Cantley, Ph.D.
June 24, 2010
Agios Appoints John Maraganore, Ph.D., to Board of Directors
April 21, 2010
Agios Scientists Present IDH1 Data at 2010 AACR Meeting
April 15, 2010
Celgene Corporation and Agios Pharmaceuticals Announce Global Strategic Collaboration to Advance Unique Science of Cancer Metabolism
March 11, 2010
Agios Pharmaceuticals Appoints William Kaelin Jr., M.D., to Scientific Advisory Board
December 21, 2009
Agios Pharmaceuticals Awarded Funding From Accelerate Brain Cancer Cure (ABC2) to Support Research into Novel Therapeutics and Diagnostics for Brain Cancer
November 23, 2009
Agios Publishes Groundbreaking Research in Nature Uncovering the New Role of IDH1 Gene Mutation in Brain Cancer
June 29, 2009
FierceBiotech Names Agios Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2009
May 28, 2009
Agios Pharmaceuticals' Focus of Drug Research - Cancer Metabolism - Selected for Stand Up To Cancer Grant
May 27, 2009
Agios Pharmaceuticals Appoints David Schenkein, M.D., as CEO and Duncan Higgons as COO
April 30, 2009
Agios Pharmaceuticals Highlights Extensive Cancer Metabolism Research at AACR
February 6, 2009
Agios Pharmaceuticals Appoints Charles Sawyers, M.D.,to Scientific Advisory Board
November 24, 2008
Agios Pharmaceuticals Attracts Leading Cancer Metabolism Experts to Advisory Team
November 24, 2008
Agios Pharmaceuticals Expands Into 21,000 SqFt Facility
July 7, 2008
Agios Pharmaceuticals Closes $33 Million Series A Funding